Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunocore Holdings (IMCR)
NASDAQ:IMCR
Immunocore Holdings (IMCR) Stock Price & Analysis
83 Followers
IMCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$41.25 - $69.06
Previous Close$49.5
Volume514.73K
Average Volume (3M)199.77K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)£332.54M
Total Debt (Recent Filing)£69.30M
Price to Earnings (P/E)-17.4
Beta0.61
Next Earnings
Nov 08, 2023EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.85
Shares Outstanding48,379,410
10 Day Avg. Volume272,981
30 Day Avg. Volume199,767
Standard Deviation0.15
R-Squared0.05
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)8.07
Price to Sales (P/S)16.59
Price to Cash Flow (P/CF)N/A
P/FCF Ratio404.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$81.89Price Target Upside59.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Immunocore Holdings News
Press ReleasesImmunocore to present at upcoming investor conferences
Press ReleasesImmunocore to present at upcoming investor conferences
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMCR FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was $41.25 and its highest was $69.06 in the past 12 months.
What is Immunocore Holdings’s market cap?
Currently, no data Available
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is Nov 08, 2023 which is in 47 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on Aug 10, 2023. The company reported -$0.357 earnings per share for the quarter, beating the consensus estimate of -$0.377 by $0.02.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -$0.32.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 48,088,345 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of -$0.357 in its last earnings report, beating expectations of -$0.377. Following the earnings report the stock price went down -3.671%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Among the largest hedge funds holding Immunocore Holdings’s share is Baker Bros Advisors LP. It holds Immunocore Holdings’s shares valued at 151M.
---
Immunocore Holdings Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.89 (59.63% Upside)
$81.89 (59.63% Upside)
Blogger Sentiment
Bullish
IMCR Sentiment 100%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.93%
12-Months-Change
Fundamentals
Return on Equity
-21.77%
Trailing 12-Months
Asset Growth
55.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunocore Holdings
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases.
---
Top 5 ETFs holding IMCR
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold IMCR. The ETFs are listed according to market value of IMCR within the ETF
Adaptimmune Therapeutics
―
Arrowhead Pharmaceuticals
―
GlycoMimetics
―
Kura Oncology
―
---